sever
acut
respiratori
syndrom
coronaviru
emerg
caus
agent
novel
pandem
viral
diseas
approv
therapi
pandem
illustr
urgent
need
safe
broadspectrum
antivir
countermeasur
futur
emerg
cov
report
remdesivir
rdv
monophosphoramid
prodrug
adenosin
analog
potent
inhibit
replic
human
lung
cell
primari
human
airway
epitheli
cultur
weaker
activ
observ
vero
cell
due
low
capac
metabol
rdv
rapidli
evalu
vivo
efficaci
engin
chimer
cov
encod
viral
target
rdv
rnadepend
rna
polymeras
mice
infect
chimer
viru
therapeut
rdv
administr
diminish
lung
viral
load
improv
pulmonari
function
compar
vehicl
treat
anim
data
provid
evid
rdv
certifi
peer
review
rna
polymeras
therapeut
mous
cadenosin
analog
potent
inhibit
replic
broad
spectrum
prepandem
bat
cov
human
epidem
cov
primari
human
lung
cell
cultur
agostini
et
al
brown
et
al
sheahan
et
al
biochem
analysi
mechan
inhibit
merscov
rnadepend
rna
polymeras
rdrp
reveal
incorpor
activ
metabolit
rdv
triphosph
rdvtp
effici
natur
substrat
atp
led
delay
chain
termin
three
nucleotid
downstream
incorpor
gordon
et
al
prolong
passag
murin
hepat
viru
mhv
group
cov
presenc
result
low
level
resist
mutat
rdrp
implic
protein
drug
target
agostini
et
al
rdv
show
prophylact
therapeut
efficaci
mous
model
sar
mer
merscov
challeng
rhesu
macaqu
model
sheahan
et
al
sheahan
et
al
wit
et
al
report
rdv
potent
inhibit
replic
human
lung
cell
submicromolar
primari
human
airway
epitheli
cultur
hae
nanomolar
notabl
detect
compar
lower
potenc
rdv
establish
human
monkey
cell
line
due
lower
metabol
capac
activ
compound
certifi
peer
review
four
endem
human
cov
typic
caus
mild
respiratori
diseas
common
coldlik
symptom
merscov
caus
sever
respiratori
diseas
respect
mortal
rate
chanyeung
xu
arabi
et
al
estim
chen
develop
effect
broadspectrum
antivir
hamper
viral
divers
capac
cov
adapt
overcom
neg
select
pressur
abil
activ
counteract
drug
action
proofread
exoribonucleas
previous
report
remdesivir
rdv
monophosphoramid
prodrug
mice
infect
chimer
encod
rdrp
treat
therapeut
rdv
show
decreas
viral
load
lung
increas
pulmonari
function
data
emphas
potenti
rdv
promis
countermeasur
ongo
pandem
replic
cell
type
infecti
viral
titer
viral
genom
copi
number
supernat
quantifi
plaqu
assay
rtqpcr
respect
rdv
potent
inhibit
replic
dosedepend
manner
cell
type
fig
tabl
cell
compound
display
dosedepend
inhibit
viral
replic
determin
plaqu
assay
fig
rtqpcr
fig
rdv
inhibit
parent
compound
less
potent
fig
tabl
valu
determin
quantif
viral
genom
copi
roughli
twofold
higher
obtain
quantif
infecti
viru
fig
tabl
compound
also
display
dosedepend
inhibit
viral
replic
vero
cell
determin
infecti
viral
titer
genom
copi
number
fig
rdv
inhibit
potent
fig
tabl
rel
potenc
base
genom
copi
similar
assess
quantif
infecti
viral
titer
vero
cell
fig
tabl
thu
rdv
inhibit
potent
vero
cell
hae
cultur
primari
hae
cultur
grown
airliquid
interfac
recapitul
cellular
complex
physiolog
human
conduct
airway
sim
et
al
therefor
evalu
antivir
activ
rdv
biolog
relev
model
rdv
treat
hae
observ
dosedepend
reduct
infecti
viru
product
inhibit
highest
test
concentr
fig
importantli
rdv
demonstr
potent
antivir
activ
valu
two
independ
experi
fig
previous
report
rdv
cytotox
dose
cultur
system
support
conclus
observ
antivir
effect
virusspecif
sheahan
et
al
togeth
data
demonstr
rdv
potent
antivir
primari
human
lung
cultur
select
index
differ
cell
cultur
model
rdv
undergo
intracellular
convers
activ
metabolit
rdvtp
involv
sever
metabol
step
fig
effici
step
might
differ
cell
type
therefor
reconcil
differ
antivir
activ
rdv
observ
studi
compar
intracellular
rdvtp
concentr
vero
hae
follow
incub
two
compound
rdvtp
level
per
million
cell
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
produc
treatment
rdv
substanti
higher
primari
hae
cultur
either
vero
fig
tabl
tabl
given
primari
natur
hae
cultur
use
cell
two
independ
donor
similar
demograph
profil
rdvtp
effici
form
donor
cultur
follow
incub
rdv
differ
lowest
level
rdvtp
observ
follow
rdv
treatment
vero
cell
approxim
lower
observ
hae
cultur
respect
level
well
intermedi
monoand
diphosphoryl
metabolit
rdvmp
rdvdp
readili
detect
cultur
follow
treatment
rdv
limit
quantif
vero
cell
time
point
test
tabl
addit
incub
vero
cell
yield
higher
rdvtp
level
compar
incub
rdv
correspond
higher
antivir
potenc
rel
rdv
observ
either
hae
cultur
tabl
conclus
rdvtp
level
differ
cell
type
directli
correl
antivir
potenc
rdv
hae
cultur
produc
substanti
higher
level
rdvtp
translat
markedli
potent
antivir
activ
rdv
tabl
importantli
metabol
rdv
vero
cell
appear
alter
less
effici
particularli
comparison
hae
cultur
indic
vero
cell
might
adequ
cell
type
character
antivir
activ
rdv
potenti
also
nucleotid
prodrugbas
antivir
determin
whether
rdv
exert
antivir
effect
vivo
construct
chimer
mouseadapt
variant
encod
target
rdv
antivir
activ
rdrp
fig
although
chimer
replicas
orf
recombin
cov
shown
viabl
stobart
et
al
first
demonstr
rdrp
relat
differ
cov
support
effici
replic
anoth
recoveri
sequenceconfirm
fig
recombin
chimer
virus
without
nanoluciferas
report
compar
replic
sensit
rdv
cell
replic
virus
inhibit
similarli
dosedepend
manner
rdv
mean
mean
fig
sought
determin
therapeut
efficaci
rdv
mous
model
employ
previou
studi
rdv
sheahan
et
al
mice
produc
serum
esteras
absent
human
carboxyl
esteras
dramat
reduc
halflif
rdv
thu
mirror
pharmacokinet
observ
human
mous
studi
rdv
must
perform
transgen
mice
sheahan
et
al
infect
femal
mice
pfu
initi
subcutan
treatment
mgkg
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
rdv
bid
one
day
postinfect
dpi
regimen
continu
studi
termin
weight
loss
differ
vehicleand
rdvtreat
anim
fig
lung
hemorrhag
five
dpi
significantli
reduc
rdv
treatment
fig
gain
insight
physiolog
metric
diseas
sever
measur
pulmonari
function
daili
whole
bodi
plethysmographi
wbp
wbp
metric
penh
surrog
marker
pulmonari
obstruct
menacheri
et
al
therapeut
rdv
significantli
amelior
loss
pulmonari
function
observ
vehicletr
group
fig
importantli
rdv
treatment
dramat
reduc
lung
viral
load
fig
taken
togeth
data
demonstr
therapeut
administ
rdv
reduc
viru
replic
mice
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
versu
isol
use
previous
mention
studi
assess
rdv
potenc
reveal
consensu
chang
sequenc
suggest
isolatespecif
variat
rdv
sensit
like
due
differ
rdvtp
interact
rdrp
therefor
differ
may
partial
explain
intrins
differ
viru
isol
quantif
method
assay
condit
incub
period
viru
input
metabolit
suggest
alter
uptak
andor
intracellular
metabol
rdv
consist
previou
report
describ
ineffici
metabol
nucleotid
prodrug
sofosbuvir
vero
cell
mumtaz
et
al
drug
potenc
vero
similar
whether
quantifi
infecti
viru
genom
copi
number
cell
potenc
determin
rtqpcr
twofold
lower
quantifi
plaqu
assay
possibl
rtqpcr
develop
detect
nucleocapsid
n
rna
also
detect
packag
subgenom
rna
defect
genom
addit
fulllength
genom
would
result
underestim
reduct
infecti
titer
notabl
potenc
rdv
encod
rdrp
cell
higher
rdv
bonafid
cell
differ
could
due
infect
driven
instead
spike
protein
addit
infect
cell
low
frequenc
moi
use
studi
appear
spread
throughout
cultur
cours
experi
number
cell
viru
replic
rel
lower
compar
cell
possibl
enhanc
potenc
rdv
compar
interestingli
antivir
potenc
rdv
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
cov
pandem
largescal
deploy
antivir
monotherapi
creat
high
risk
emerg
drug
resist
previou
work
demonstr
cov
resist
rdv
gener
slowli
confer
two
mutat
rdrp
addit
rdvresist
cov
exhibit
reduc
replic
capac
also
sensit
anoth
potent
activ
nucleosid
analog
inhibitor
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
thank
dr
natali
thornburg
center
diseas
control
prevent
atlanta
usa
provid
stock
use
studi
final
thank
vumc
unc
environment
health
safeti
personnel
ensur
work
perform
safe
secur
also
thank
facil
manag
personnel
tireless
commit
excel
facil
perform
grant
manag
team
administr
support
research
oper
author
affili
gilead
scienc
inc
employe
compani
compani
stock
author
conflict
interest
report
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
box
encompass
th
th
percentil
line
drawn
median
whisker
repres
rang
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
transwellcol
diamet
support
corn
human
airway
epithelium
cultur
hae
gener
provis
airliquid
interfac
week
form
welldifferenti
polar
cultur
resembl
vivo
pseudostratifi
mucociliari
epithelium
fulcher
et
al
clinic
specimen
casepati
acquir
travel
china
diagnos
washington
state
usa
upon
return
collect
describ
holshu
et
al
viru
isol
patient
specimen
perform
describ
harcourt
et
al
sequenc
avail
genbank
access
number
passag
stock
seattl
isol
obtain
cdc
pass
twice
vero
cell
gener
hightit
passag
stock
experi
describ
manuscript
express
gfp
gfp
replac
creat
molecular
cdna
clone
describ
scobey
et
al
sim
et
al
creat
express
nanoluciferas
nluc
gene
gfp
replac
nluc
isol
use
exist
mous
adapt
urbani
molecular
clone
yount
et
al
synthet
cdna
encod
rdrp
integr
dna
technolog
clone
sar
fragment
use
stui
bsai
via
gibson
assembl
result
plasmid
sequenc
confirm
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
quantif
infecti
viral
titer
plaqu
assay
approxim
x
vero
cellswel
seed
tissu
cultur
plate
corn
allow
grow
confluenc
h
medium
remov
serial
dilut
viruscontain
supernat
gel
salin
adsorb
duplic
min
plate
rock
manual
redistribut
inoculum
everi
minut
cell
overlaid
mixtur
dmem
agar
incub
plaqu
enumer
unstain
monolay
hpi
use
light
box
n
gene
posit
control
plasmid
idt
cat
serv
templat
pcramplifi
bp
product
use
forward
revers
primer
append
rna
polymeras
promot
end
complet
n
orf
pcr
product
column
purifi
promega
subsequ
vitro
transcript
n
rna
use
mmessag
mmachin
transcript
kit
invitrogen
accord
manufactur
protocol
n
rna
purifi
use
rneasi
mini
kit
qiagen
accord
manufactur
protocol
copi
number
calcul
use
scienceprimercom
cop
number
calcul
vitro
metabol
rdv
vero
cell
seed
plate
x
x
cellswel
respect
twentyfour
hour
later
cell
cultur
media
replac
media
contain
rdv
incub
differenti
hae
cultur
two
healthi
donor
mattek
corpor
ashland
maintain
media
replac
everi
day
week
hae
donor
femal
race
time
treatment
media
replac
basal
side
transwel
hae
cultur
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
apic
surfac
media
replac
media
contain
rdv
post
drug
addit
cultur
cell
wash
time
icecold
trisbuff
salin
scrape
ml
icecold
methanol
store
extract
centrifug
x
g
minut
supernat
transfer
clean
tube
evapor
mivac
duo
concentr
genevac
dri
sampl
reconstitut
mobil
phase
contain
mm
ammonium
format
ph
mm
dimethylhexylamin
dmh
water
analysi
lcmsm
use
multistag
linear
gradient
acetonitril
mobil
phase
flow
rate
analyt
separ
use
x
mm
luna
hst
column
phenomenex
connect
shimadzu
ternari
pump
system
ht
pal
autosampl
leap
technolog
detect
perform
qtrap
ab
sciex
mass
spectromet
oper
posit
ion
multipl
reaction
monitor
mode
analyt
quantifi
use
standard
curv
rang
concentr
pmol
prepar
extract
untreat
cell
normal
cell
number
multipl
untreat
vero
cultur
well
count
timepoint
hae
cell
count
timepoint
count
timepoint
determin
normal
endogen
atp
level
accuraci
formul
vivo
studi
rdv
solubil
mgml
vehicl
contain
sodium
salt
water
hclnaoh
ph
vivo
efficaci
studi
anim
experi
perform
accord
univers
north
carolina
chapel
hill
institut
anim
care
use
committe
polici
guidelin
achiev
pharmacokinet
profil
similar
observ
human
perform
therapeut
efficaci
studi
mice
stock
jackson
laboratori
lack
serum
esteras
present
human
dramat
reduc
rdv
halflif
sheahan
et
al
weekold
femal
mice
anaesthet
mixtur
ketaminexylazin
intranas
infect
pfu
one
dpi
vehicl
n
rdv
n
dose
initi
mgkg
subcutan
continu
everi
h
end
studi
five
dpi
monitor
morbid
mice
weigh
daili
pulmonari
function
test
perform
daili
whole
bodi
plethysmographi
wbp
data
scienc
intern
sheahan
et
al
five
dpi
anim
sacrif
isofluran
overdos
lung
score
lung
hemorrhag
inferior
right
lobe
frozen
viral
titrat
via
plaqu
assay
vero
cell
lung
hemorrhag
gross
patholog
phenotyp
readili
observ
nake
eye
driven
degre
viru
replic
lung
color
chang
pink
dark
red
sheahan
et
al
sheahan
et
al
plaqu
assay
x
vero
cellswel
seed
plate
follow
day
medium
remov
monolay
adsorb
one
h
serial
dilut
sampl
rang
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
cell
overlay
dmem
fetal
clone
serum
antibioticantimycot
agaros
viral
plaqu
enumer
three
day
later
mathemat
statist
analys
valu
defin
graphpad
prism
concentr
decreas
viral
replic
rel
vehicl
alon
inhibit
curv
fit
base
four
paramet
nonlinear
regress
analysi
statist
test
execut
use
graphpad
prism
